Posted by Michael Wonder on 13 Dec 2021
Veru announces FDA approval of Entadfi, a new treatment for benign prostatic hyperplasia
13 December 2021 - Commercialisation will start early calendar year 2022.
Veru announced today that the U.S. FDA has approved Entadfi for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia.
